Natural Killer Cell-Dependent Anti-Fibrotic Pathway in Liver Injury via Toll-Like Receptor-9
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The toll-like receptor-9 (TLR9) agonist cytosine phosphate guanine (CpG), activates hepatic stellate cells (HSCs) and mediates fibrosis. We investigated the TLR9 effects on lymphocyte/HSCs interactions. Liver fibrosis was induced in wild-type (WT) mice by intra-peritoneal carbon-tetrachloride (CCl4) induction for 6 weeks. Fibrotic groups were intravenously treated by a vehicle versus CpG along last 2 weeks. Compared to vehicle-treated fibrotic WT, the in-vivo CpG-treatment significantly attenuated hepatic fibrosis and inflammation, associated with decreased CD8 and increased NK liver cells. In-vitro, co-cultures with vehicle-treated fibrotic NK cells increased HSCs proliferation (P<0.001) while their CpG-treated counterparts achieved a significant decrease. To investigate the role of lymphocytes, TLR9(-/-) mice induced-hepatic fibrosis were used. Although TLR9(-/-) mice manifested lower fibrotic profile as compared to their wild-type (WT) counterparts, senescence (SA-β-Gal activity) in the liver and ALT serum levels were significantly greater. In an adoptive transfer model; irradiated WT and TLR9(-/-) recipients were reconstituted with naïve WT or TLR9(-/-) lymphocytes. The adoptive transfer of TLR9(-/-) versus WT lymphocytes led to increased fibrosis of WT recipients. TLR9(-/-) fibrotic recipients reconstituted with TLR9(-/-) or WT lymphocytes showed no changes in hepatic fibrosis severity or ALT serum levels. TLR9 activation had inconsistent effects on lymphocytes and HSCs. The net balance of TLR9 activation in WT, displayed significant anti-fibrotic activity, accompanied by CD8 suppression and increased NK-cells, activity and adherence to HSCs. The pro-fibrotic and pro-inflammatory properties of TLR9(-/-) lymphocytes fail to activate HSCs with an early senescence in TLR9(-/-) mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Natural killer (NK) cells have an intriguing capacity to clear activated HSCs (91-94).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [92]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“Sections were counterstained with Eosin [15,24,25].”
Toll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328 · cited 1×
“TLR9, a member of the TLR family, is expressed intracellularly, within endosomal compartments [5], and activates innate immune defenses against viral and bacterial infection upon binding to DNA rich in cytosine phosphate guanine (CpG) motifs [6].”
BackgroundTakeda, K., & Akira, S. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2003.10.003 · Cited by 2,461
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Self-citationTLR9 signals after translocating from the ER to CpG DNA in the lysosome
Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G., Knetter, C. F., Lien, E., Nilsen, N. J., Espevik, T., & Golenbock, D. T. (2004) · Nature Immunology · doi:10.1038/ni1028 · Cited by 1,361
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 1×
“TLR9 pathways are involved in the modulation of liver diseases [29].”
BackgroundPaik, Y.-H., Schwabe, R. F., Bataller, R., Russo, M. P., Jobin, C., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50182 · Cited by 651
Research works printed but not linked: 1
- Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5(6): 471- 484. doi: 10.1038/nrd2059. PubMed: 16763660. 16763660 · DOI · Paper page
Cited by
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Weiskirchen, R., & Tacke, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3881.2014.11.03 · Cited by 256
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease
Khanmohammadi, S., & Kuchay, M. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106507 · Cited by 108
Fang, F., Marangoni, R. G., Zhou, X., Yang, Y., Ye, B., Shangguang, A., Qin, W., Wang, W., Bhattacharyya, S., Wei, J., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39655 · Cited by 76
Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances
Laurent, P., Sisirak, V., Lazaro, E., Richez, C., Duffau, P., Blanco, P., Truchetet, M., & Contin‐Bordes, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01702 · Cited by 69
Insulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease
Amer, J., Salhab, A., Noureddin, M., Doron, S., Abu‐Tair, L., Ghantous, R., Mahamid, M., & Safadi, R. (2018) · Hepatology Communications · doi:10.1002/hep4.1146 · Cited by 42
Self-citationThe A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice
Fishman, P., Cohen, S., Itzhak, I., Amer, J., Salhab, A., Barer, F., & Safadi, R. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4364 · Cited by 51
Self-citationCrosstalk between NK cells and hepatic stellate cells in liver fibrosis (Review)
Zhang, Y., Wu, Y., Shen, W., Wang, B., & Yuan, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12724 · Cited by 35
Toll Like Receptors in systemic sclerosis: An emerging target
O’Reilly, S. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.09.001 · Cited by 38
Jannone, G., Rozzi, M., Najimi, M., Decottignies, A., & Sokal, E. M. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420913534 · Cited by 40
Gut microbiota in MAFLD: therapeutic and diagnostic implications
Alghamdi, W., Mosli, M. H., & Alqahtani, S. A. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241242937 · Cited by 34
The antifibrotic role of natural killer cells in liver fibrosis
Wei, Y., Bingyu, W., Yang, L., & Yuan, X. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221092672 · Cited by 32
The Deficiency of Indoleamine 2,3-Dioxygenase Aggravates the CCl4-Induced Liver Fibrosis in Mice
Ogiso, H., Ito, H., Ando, T., Arioka, Y., Kanbe, A., Ando, K., Ishikawa, T., Saito, K., Hara, A., Moriwaki, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162183 · Cited by 27
Natural killer cells in liver diseases
Zheng, M., Sun, H., & Tian, Z. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0621-4 · Cited by 27
Milman, Z., Axelrod, J. H., Heyman, S. N., Nachmansson, N., & Abramovitch, R. (2014) · American Journal of Nephrology · doi:10.1159/000360093 · Cited by 15
Self-citationAmiot, L., Vu, N., Drénou, B., Scrofani, M., Chalin, A., Devisme, C., & Samson, M. (2019) · Cytokine · doi:10.1016/j.cyto.2019.02.002 · Cited by 15
An Overview of the Mechanisms of Cadmium-induced Toxicity in the Male Reproductive System
Antar, S. A., Halouani, A., Gad, C., & Al-Karmalawy, A. A. (2023) · Pharmaceutical Sciences · doi:10.34172/ps.2023.10 · Cited by 10
Ho, S., McLachlan, A. J., Chen, T. F., Hibbs, D., & Fois, R. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.56 · Cited by 15
The possible pathogenesis of liver fibrosis: therapeutic potential of natural polyphenols
Niu, C., Zhang, J., & Okolo, P. I., III (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00638-w · Cited by 8
Huang, S.-C., Fu, Y.-F., Rehman, M. U., Li, K., Lan, Y., Liu, W., Luo, H., Zhang, H., Zhang, L., Hao, Y., et al. (2018) · Animal Production Science · doi:10.1071/an16423 · Cited by 4
Biomarkers of Replicative Senescence Revisited
Nehlin, J. O. (2016) · Healthy ageing and longevity · doi:10.1007/978-3-319-26239-0_12 · Cited by 2
Miura, K., & Ohnishi, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55790-6_1 · Cited by 2
Friedman, S. L. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch10 · Cited by 1
Bansal, M. B., & Friedman, S. L. (2018) · Wiley eBooks · doi:10.1002/9781119237662.ch6 · Cited by 5
Chemokine receptors as therapeutic targets in liver disease
Parker, R. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
Context-dependent duality of senescent cells in liver fibrosis
Gu, Y., Zhan, L., Di, Y., Wu, H., Zhao, T., Zhang, F., & Wu, Q. (2026) · Liver Research · doi:10.1016/j.livres.2026.09.001
Metadata
- Authors
- Abu-Tair, L., Axelrod, J. H., Doron, S., Ovadya, Y., Krizhanovsky, V., Galun, E., Amer, J., & Safadi, R.
- Affiliations
- Hadassah Medical Center (IL)
- Weizmann Institute of Science (IL)
- Corresponding author
- Amer, Johnny
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-10
- Volume
- 8
- Issue
- 12
- Pages
- e82571
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3858328
- OpenAlex
- W2088878850
- Cited by
- 28
- References
- 40
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 2
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Hadassah Medical Organization
- Israel Science Foundation (1169/09)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver fibrosis, TLR9, natural killer cells, hepatic stellate cells, CpG oligodeoxynucleotides, carbon tetrachloride-induced liver injury, CD8+ T cells, cellular senescence, adoptive transfer, antifibrotic therapy, liver inflammation
- MeSH terms
- Adjuvants, Immunologic, Animals, Carbon Tetrachloride Poisoning, Cell Communication, Killer Cells, Natural, Liver Cirrhosis, Oligodeoxyribonucleotides, Mice, Knockout, CD8-Positive T-Lymphocytes, Adoptive Transfer, Toll-Like Receptor 9, Mice, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.